Scientific Program - Stroke

Print
Please see below the CONy Scientific Program. Please click on the appropriate section (ordered by ABC) to view the relevant program. Please note that the program and timing is subject to change. To view the program timetable, please click here
 

Section Heads: Natan Bornstein, Israel & Georgios Tsivgoulis, Greece
SATURDAY, MARCH 25, 2017
Hall B
08:30-10:30
STROKE
Chairs: Georgios Paraskevas, Greece; Rahim Aliyev, Azerbaijan
Proposition: Neurosonology is useful in acute ischemic stroke (AIS) management
Capsule:
Neuroimaging plays an imporatant role in the assmemnt of acute stroke patients. However, the usefulness of Doppler ultrasound in AIS mangament is still uncertain and will be discussed.
Host: Laszlo Csiba, Hungary
Yes: Andrei V. Alexandrov, USA
No: Vasileios-Arsenios Lioutas, USA
Discussion and rebuttals


Proposition: Patients with embolic stroke of undetermined source (ESUS) need to be anticoagulated
Capsule: Many AIS are cryptogenic, and may represent ESUS. ''Silent'' paroxysmal AF may be detected in some by longterm ECG monitoring. Should those with AF shorter than 30'' also be anticoagulated?
Host: Danuta Ryglewicz, Poland
Yes: Martin Kohrmann, Germany
No: Natan Bornstein, Israel

Discussion and rebuttals

10:45-12:45 THROMBOLYSIS AND THROMBECTOMY: TO WHOM AND WHEN?
Chairs: Theodore Karapanay, Greece; Roni Eichel, Israel
Proposition: Intravenous thrombolysis is effective in wake-up stroke with normal baseline CT
Capsule: Wake-up strokes account for about 20% of AIS and present a therapeutic dilemma. Can a normal CT help in selecting patients for thrombolysis?

Host: Andrew Demchuk, Canada
Yes: Christos Krogias, Germany
No: Panos Mitsias, Greece
Discussion and rebuttals
Proposition: Mechanical thrombectomy is effective in M2 occlusions
Capsule: Recently thrombectomy was proven to be beneficial in patients with acute major artery (eg M1) occulsions. However, its usefulness in smaller arteries (eg M2) is still uncertain and will be debated.
Host: Georgios Tsivgoulis, Greece
Yes: Andrew Demchuk, Canada
No: Vasileios-Arsenios Lioutas, USA
Discussion and rebuttals
15:00-17:00
STROKE: ROLE OF ANTICOAGULANTS
Chair: Odysseas Kargiotis, Greece
Debate: What is the optimal anticoagulation for secondary stroke prevention of NVAF patients with good (>66%) TTR?
Host: Martin Kohrmann, Germany
NOACs: Laszlo Csiba, Hungary
VKA: Safouris Apostolos, Greece
Discussion and rebuttals
Proposition: Anticoagulation therapy should not be restarted in patients with anticoagulation-related lobar intracerebral hemorrhage
Capsule:
Capsule: The current recommendation for patients with NVAF who experienced a lobar hemorrhage while antiaocagulated is to refrain from restarting anticoagulants. Is this policy correct?
Host: David Werring, UK
Fact: Edip Gurol, USA
Fiction: Jonathan Streifler, Israel
Discussion and rebuttals
17:00-19:00
STROKE: ROLE OF STATINS


Debate: High-dose statins should be administered in all patients with acute large artery atherosclerotic stroke
Capsule:
The risk of intracerebral hemorrhage (ICH) is higher in patients comedicated with statins and SSRI's. Should these drugs be discontinued following ICH?
Host: Andrei Alexandrov, USA
Yes: Georgios Tsivgoulis, Greece
No: Christos Krogias, Germany
Discussion and rebuttals


Debate: Statin and SSRI pretreatment should be discontinued in patients with acute intracerebral hemorrhage
Capsule: The current recommendation is to start higher dose statins in pateints with AIS due to atherschlerosis is based on a single study (SPARCL). Should statins be prescribed to all AIS patients?
Host: Jonathan Streifler, Israel
Yes: David Werring, UK
No: Edip Gurol, USA

Discussion and rebuttals